William Gerber, MD was an Investment Partner with Bay City Capital from 2004 to 2013. He is retiring from his role as Investment Partner; however, he will remain as an active advisor to the firm. Prior to his role with Bay City Capital, he was President and Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen in 2004. Prior to Epoch, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products. Dr. Gerber also served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, as President of Chiron Diagnostics, and as Senior Vice President and General Manager of the PCR Division of Cetus Corporation. Dr. Gerber is a member of the board of directors of Nabsys, Omicia, and SynGen, Inc.. He also served on and was President of the Board of Medical Quality Assurance, State of California. He received his MD and BS degrees from University of California, San Francisco Medical Center after attending Dartmouth College.